VivoSense develops novel digital endpoints and biomarkers from wearable sensor data using its proprietary VivoSense® software. The company focuses on healthcare research, clinical trials and patient wellness, aiming to produce validated digital clinical outcome assessments (COAs). It plans to expand and refine its informatics platform and accelerate development of digital biomarkers for indications including cancer, Alzheimer’s and rare disease. VivoSense emphasizes passive, body-worn monitoring to capture real-world physiologic and behavioral measures with lower patient burden than clinic-based assessments. The company conducts rigorous analytical and clinical validation intended to support regulatory and medical decision-making and pursue FDA approval for its measures. VivoSense recently closed a $25 million Series A to fund these efforts and is headquartered in Newport Beach, Calif.

Total raised

$25M

Funding rounds

1

Latest round

Series A

Latest activity

Mar 2022